Maze Therapeutics (MAZE) Operating Leases (2024 - 2026)

Maze Therapeutics has disclosed Operating Leases across 3 years of filings, most recently posting $17.6 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $17.6 million, down 17.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.6 million (down 17.01% YoY), and the FY2025 annual result was $18.5 million, down 15.84% from the prior year.
• Operating Leases came in at $17.6 million for Q1 2026 at Maze Therapeutics, down from $18.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $22.0 million in Q4 2024 to a low of $17.6 million in Q1 2026.
• The 3-year median for Operating Leases is $19.9 million (2025), against an average of $19.8 million.
• Across the five-year window, Operating Leases decreased 15.84% in 2025 and retreated 17.01% in 2026, its largest moves.
• Maze Therapeutics' Operating Leases stood at $22.0 million in 2024, then fell by 15.84% to $18.5 million in 2025, then declined by 5.18% to $17.6 million in 2026.
• The last three Operating Leases figures came in at $17.6 million (Q1 2026), $18.5 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.